CAC Score: Normal Lab Ranges vs. Functional Optimal Targets

What the CAC Score Actually Measures

The coronary artery calcium score quantifies the total burden of calcified atherosclerotic plaque inside the walls of the coronary arteries. A non-contrast CT scan of the chest takes about 10 minutes, requires no IV dye, and delivers a radiation dose roughly equivalent to a screening mammogram (approximately 1 mSv) [1].

Each area of calcification is scored using the Agatston method, first described by Arthur Agatston in 1990 [2]. The algorithm multiplies the area of each calcified lesion by a density weighting factor (1 through 4) based on its peak Hounsfield unit attenuation. All individual lesion scores are summed to produce the total Agatston score. A score of zero means the CT detected no calcified plaque whatsoever. That is not the same as saying the arteries are free of all plaque. Non-calcified ("soft") plaque can exist without contributing to the CAC number, which is an important limitation of the test [3].

The Multi-Ethnic Study of Atherosclerosis (MESA), a prospective cohort of 6,814 adults followed for over 15 years, established that the CAC score independently predicts myocardial infarction, cardiovascular death, and all-cause mortality across every racial and ethnic group studied [4]. This dataset is the foundation of the MESA CAC calculator, which reports age-, sex-, and ethnicity-specific percentiles alongside the raw Agatston number.

How Standard Lab Reporting Categorizes Your Score

Most radiology reports bucket CAC scores into four tiers. This is the convention cardiologists see on a daily basis, and it shapes the language patients hear.

The standard categories are: 0 (no identifiable disease), 1 to 99 (mild plaque), 100 to 399 (moderate plaque), and 400 or above (severe plaque) [5]. A score above 1,000 places a patient in the highest-risk subset, where 10-year major adverse cardiac event rates approach 25% in some cohorts [6].

These tiers are useful. They are also blunt. A 45-year-old woman with a score of 35 and a 72-year-old man with a score of 35 carry very different risk profiles, because the age- and sex-adjusted percentile for the younger patient is far higher. The 2019 ACC/AHA Primary Prevention Guidelines explicitly recommend using the CAC score to refine risk in adults whose 10-year atherosclerotic cardiovascular disease (ASCVD) risk falls between 7.5% and 20%, the so-called "intermediate risk" group [7]. The guideline committee gave CAC scoring a Class IIa recommendation for this population, stating that "if the CAC score is zero, it is reasonable to withhold statin therapy and reassess in 5 to 10 years."

Functional Optimal vs. Reference-Range Normal

Here is where the two frameworks diverge. Standard cardiology practice treats a score of 1 to 99 as "mild" and may or may not trigger pharmacotherapy depending on other risk factors. The functional and preventive cardiology perspective treats any score above zero as a signal that atherosclerosis has already begun and that aggressive intervention is warranted.

Dr. Matthew Budoff, a principal investigator in the MESA trial, has stated: "A CAC score of zero is the most powerful negative risk factor we have in cardiology. Once calcium appears, you cannot un-ring that bell" [8]. This framing redefines "optimal" not as a range, but as a single number: zero.

The clinical logic behind this position is straightforward. Coronary calcium does not regress. High-intensity statin therapy can slow the rate of calcium progression, but it does not reverse existing calcification [9]. Data from the St. Francis Heart Study showed that patients with baseline CAC scores above 400 who were randomized to atorvastatin 20 mg daily had a 42% reduction in coronary events compared with placebo, yet their CAC scores continued to rise on follow-up CT [10]. The plaque stabilized. It did not disappear.

So the functional optimal target is zero, maintained for as long as possible through lipid management, blood pressure control, glycemic optimization, smoking cessation, and exercise. Once the score rises above zero, the goal shifts to slowing progression rather than achieving regression.

Why a "Normal" Score of 50 Is Not the Same as Optimal

Consider a practical scenario. A 52-year-old man with a CAC score of 50 would be told his result falls in the "mild" category. His report might even note that his score places him at the 50th percentile for his age and sex, which sounds reassuringly average.

But average is not safe. In the MESA cohort, participants with CAC scores between 1 and 100 had a 3.6-fold higher rate of coronary heart disease events compared with those who scored zero over a median follow-up of 11.1 years (HR 3.61 to 95% CI 2.81 to 4.63) [4]. A score of 50 is dramatically better than a score of 500, but it is dramatically worse than a score of zero.

The 2018 Cholesterol Guideline from the ACC/AHA notes that "a CAC score of 1 to 99 favors statin therapy, especially in those ≥55 years of age" [7]. For younger patients with scores in this range, the decision becomes more nuanced, weighing family history, LDL-C levels, inflammatory markers like high-sensitivity C-reactive protein (hs-CRP), and lipoprotein(a) concentration.

Dr. Khurram Nasir, a cardiovascular epidemiologist at Houston Methodist, has summarized the shift: "We've moved from asking 'is this score normal for your age' to asking 'is there any calcium at all, and if so, what are we going to do about it'" [11]. That reframing captures the functional vs. conventional divide.

Percentile Context: The MESA Calculator

Raw Agatston numbers gain far more clinical meaning when placed into percentile context. The MESA CAC calculator (available through the MESA-NHLBI website) generates age-, sex-, and ethnicity-adjusted percentiles using data from the original MESA cohort [12].

A score of 10 in a 45-year-old Black woman might place her above the 90th percentile for her demographic group, indicating she has more calcified plaque than 90% of comparable women. The same score in a 70-year-old white man might fall below the 25th percentile. Percentile context changes the clinical interpretation completely.

The 2019 ACC/AHA guideline endorses using this percentile data to guide statin discussions [7]. A CAC score at or above the 75th percentile for age and sex should prompt serious consideration of statin therapy, regardless of the absolute Agatston number. A score at or below the 25th percentile, particularly if zero, provides reassurance that near-term risk is low.

What Drives a CAC Score Higher Over Time

CAC progression is not random. It tracks with the same risk factors that drive atherosclerosis more broadly. Annual CAC progression rates average 20% to 25% per year in untreated patients with established coronary calcium [13]. That means a score of 100 can become a score of 300 within five years if risk factors remain uncontrolled.

The primary drivers include elevated LDL cholesterol (particularly when LDL-C exceeds 130 mg/dL or apolipoprotein B exceeds 90 mg/dL), hypertension, insulin resistance and type 2 diabetes, active smoking, chronic kidney disease, and elevated lipoprotein(a) [14]. Each of these accelerates the calcification process through distinct but overlapping mechanisms involving endothelial injury, lipid deposition, macrophage infiltration, and osteogenic differentiation of vascular smooth muscle cells.

The CARDIA study followed 3,043 adults from young adulthood (ages 18 to 30 at enrollment) for 25 years and found that participants with unfavorable risk factor profiles in their twenties were significantly more likely to have detectable CAC by age 45 to 55 [15]. Early-life risk factor exposure has a cumulative effect on plaque development, supporting the functional medicine emphasis on lifelong cardiovascular optimization rather than waiting until middle age to check a calcium score.

Evidence-Based Strategies to Keep Your Score at Zero (or Slow Progression)

Statin therapy is the most extensively studied pharmacologic intervention for CAC-positive patients. In the MESA cohort, statin use was associated with slower CAC progression in patients with baseline scores above zero, though paradoxically, some studies have shown slight acceleration of calcification in statin-treated patients because statins promote plaque stabilization, which involves calcification of previously soft, vulnerable plaque [9]. This is considered a favorable remodeling process, not a worsening of disease.

Beyond statins, blood pressure control to a target below 130/80 mmHg (per the 2017 ACC/AHA Hypertension Guideline) reduces the mechanical shear stress that damages endothelium and promotes plaque development [16]. Glycemic control in patients with diabetes or prediabetes limits the advanced glycation end-product (AGE) accumulation that accelerates vascular calcification. The UKPDS demonstrated that each 1% reduction in HbA1c was associated with a 14% reduction in myocardial infarction risk [17].

Exercise has independent effects. The Cooper Center Longitudinal Study found that higher cardiorespiratory fitness was associated with lower odds of having a CAC score above 100, even after adjustment for traditional risk factors (OR 0.64 to 95% CI 0.46 to 0.88 for highest vs. lowest fitness quartile) [18]. Smoking cessation, weight management, and dietary patterns emphasizing fiber, omega-3 fatty acids, and reduced processed food intake round out the evidence-based approach.

Specific supplements are sometimes promoted for calcium score reduction. Vitamin K2 (menaquinone-7) has biological plausibility because it activates matrix Gla-protein, which inhibits vascular calcification. The VitaK-CAC trial (NCT01002157) studied high-dose vitamin K2 supplementation and found a trend toward slower CAC progression, but the primary endpoint did not reach statistical significance [19]. It remains an area of active investigation, not an established therapy.

When to Get a CAC Score (and When to Skip It)

The 2019 ACC/AHA guideline identifies the sweet spot for CAC testing: adults aged 40 to 75 whose 10-year ASCVD risk falls between 7.5% and 19.9% and in whom the decision to start statin therapy is uncertain [7]. The scan is most useful as a tie-breaker. If risk calculators and clinical judgment leave the statin decision ambiguous, a CAC of zero tips the scale toward deferring, while any detectable calcium tips it toward initiating.

CAC screening is not recommended for low-risk individuals (10-year ASCVD risk <5%) because the prevalence of detectable calcium is low and the test is unlikely to change management. It is also less useful for very high-risk patients (10-year risk >20% or those with established ASCVD, familial hypercholesterolemia, or LDL-C ≥190 mg/dL) because these patients should receive statin therapy regardless of their calcium score [7].

The U.S. Preventive Services Task Force (USPSTF) issued an "I" (insufficient evidence) statement for CAC screening in 2018, reflecting their assessment that the balance of benefits and harms could not be determined for the general asymptomatic population [20]. This stands in contrast to the ACC/AHA's more targeted endorsement. The distinction matters: the USPSTF evaluates population-level screening, while the ACC/AHA recommendation applies to a specific risk stratum where clinical uncertainty exists.

Repeat Testing and Tracking Progression

If a baseline CAC score is zero, most guidelines suggest repeating the scan in 5 to 10 years unless new risk factors emerge [7]. For patients with detectable calcium, a repeat scan at 3 to 5 years can quantify progression and inform treatment intensity.

A CAC progression rate exceeding 15% per year has been associated with increased event risk in observational studies, even after adjusting for the baseline score [13]. Serial scanning is not yet a Class I guideline recommendation, but it is increasingly used in preventive cardiology practices to monitor treatment response and motivate patient adherence. Seeing their calcium score hold steady (or rise more slowly than expected) gives patients tangible evidence that their lifestyle modifications and medications are working.

Radiation exposure is a reasonable concern with serial imaging, though the dose per scan (0.7 to 1.0 mSv) is modest [1]. Over a decade of biennial scans, cumulative exposure would total approximately 5 mSv, less than the annual background radiation exposure in many U.S. cities.